$VKTX
Viking Therapeutics, Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016028979 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.090M $1.780M
YoY Change -22.14% 394.44%
% of Gross Profit
Research & Development $2.650M $2.508M
YoY Change -17.7% 217.41%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.740M $4.288M
YoY Change -19.05% 272.89%
Operating Profit -$4.288M
YoY Change
Interest Expense -$530.0K -$10.31K
YoY Change 112.0% -58.81%
% of Operating Profit
Other Income/Expense, Net $620.0K -$448.3K
YoY Change -381.82% -150.53%
Pretax Income -$3.640M -$4.740M
YoY Change -28.49% 1723.08%
Income Tax
% Of Pretax Income
Net Earnings -$3.640M -$4.737M
YoY Change -28.49% 1709.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$182.4K -$529.6K
COMMON SHARES
Basic Shares Outstanding 20.17M 9.783M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.20M $17.50M
YoY Change -6.38%
Cash & Equivalents $3.076M $2.140M
Short-Term Investments $10.10M $15.30M
Other Short-Term Assets $800.0K $1.400M
YoY Change -27.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.97M $18.93M
YoY Change -8.07%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $600.0K $80.00K
YoY Change 200.0%
Total Long-Term Assets $560.9K $80.00K
YoY Change 136.2%
TOTAL ASSETS
Total Short-Term Assets $13.97M $18.93M
Total Long-Term Assets $560.9K $80.00K
Total Assets $14.54M $19.01M
YoY Change -5.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.204M $401.7K
YoY Change 103.22%
Accrued Expenses $1.300M $1.300M
YoY Change -7.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.300M $1.900M
YoY Change
Total Short-Term Liabilities $6.477M $5.723M
YoY Change 227.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $16.31K $19.15K
YoY Change -99.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.477M $5.723M
Total Long-Term Liabilities $16.31K $19.15K
Total Liabilities $6.493M $5.742M
YoY Change -3.3%
SHAREHOLDERS EQUITY
Retained Earnings -$60.28M -$40.45M
YoY Change 32.35%
Common Stock $68.33M $53.73M
YoY Change 25.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.043M $13.27M
YoY Change
Total Liabilities & Shareholders Equity $14.54M $19.01M
YoY Change -5.85%

Cashflow Statement

Concept 2016 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$3.640M -$4.737M
YoY Change -28.49% 1709.22%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.460M -$3.400M
YoY Change -25.45% 457.38%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.450M -$3.260M
YoY Change -26.02%
Cash From Investing Activities $1.450M -$3.260M
YoY Change -26.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.040M -710.0K
YoY Change -3566.67% -236.54%
NET CHANGE
Cash From Operating Activities -2.460M -3.400M
Cash From Investing Activities 1.450M -3.260M
Cash From Financing Activities 1.040M -710.0K
Net Change In Cash 30.00K -7.370M
YoY Change -102.19% 8088.89%
FREE CASH FLOW
Cash From Operating Activities -$2.460M -$3.400M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20170264
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
768550
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
13335499
CY2016Q3 vktx Deferred Public Offering And Other Financing Costs Noncurrent
DeferredPublicOfferingAndOtherFinancingCostsNoncurrent
614380
CY2015Q4 vktx Accrued Interest Non Current
AccruedInterestNonCurrent
183611
CY2016Q3 vktx Convertible Notes Payable Discount Noncurrent
ConvertibleNotesPayableDiscountNoncurrent
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3628747
us-gaap Operating Expenses
OperatingExpenses
7376175
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.69
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15052139
us-gaap Net Income Loss
NetIncomeLoss
-11087213
us-gaap Operating Income Loss
OperatingIncomeLoss
-7376175
vktx Change In Fair Value Of Accrued License Fees
ChangeInFairValueOfAccruedLicenseFees
-9381848
vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
444083
vktx Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
-826637
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1356861
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
652986
CY2016Q3 vktx Amortization Of Financing Costs Equity Transactions
AmortizationOfFinancingCostsEquityTransactions
45852
vktx Amortization Of Financing Costs Equity Transactions
AmortizationOfFinancingCostsEquityTransactions
45852
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-18832
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-75379
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-977462
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10936850
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6802169
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
116962
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
67692
us-gaap Share Based Compensation
ShareBasedCompensation
2074004
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-92129
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1504027
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
300360
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
137286
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-422999
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1244495
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8606379
us-gaap Share Based Compensation
ShareBasedCompensation
1435752
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
418412
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
38
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
10943
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1582549
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10444522
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1024581
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
25851
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2152
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5432104
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12263451
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
16033042
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
13846000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
607000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-15426042
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25392500
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2733798
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
94861
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9310172
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
22242404
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2286342
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1384258
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
755857
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2140115
us-gaap Interest Paid
InterestPaid
205139
vktx Stock Issued In Lieu Of License Fee Payment To Related Party
StockIssuedInLieuOfLicenseFeePaymentToRelatedParty
29247711
vktx Stock Issued In Lieu Of Loan Payment To Related Party
StockIssuedInLieuOfLoanPaymentToRelatedParty
1200000
vktx Unpaid Deferred Initial Public Offering And Other Financing Costs
UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts
71617
us-gaap Stock Issued1
StockIssued1
440278
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
456412
vktx Issuance Of Common Stock To Consultant
IssuanceOfCommonStockToConsultant
28760
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion feature liability and accounting for certain commitments. Actual results could differ from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-09-24
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7500000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7500000
CY2016Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7754286
CY2016Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.25
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2016Q2 vktx Additional Shares Offered Under Underwriting Agreement
AdditionalSharesOfferedUnderUnderwritingAgreement
1125000
CY2016Q2 vktx Underwriters Grant Period Option
UnderwritersGrantPeriodOption
P45D
CY2016Q2 vktx Additional Warrants Granted To Underwriters
AdditionalWarrantsGrantedToUnderwriters
1125000
CY2016Q2 vktx Additional Warrants Sold As Result Of Over Allotment Exercise
AdditionalWarrantsSoldAsResultOfOverAllotmentExercise
1125000
CY2016Q2 us-gaap Share Price
SharePrice
0.01
CY2016Q2 vktx Class Of Warrants Or Rights Expiry Date
ClassOfWarrantsOrRightsExpiryDate
2021-04-13
CY2016Q2 vktx Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
1631964
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
13573619
CY2015 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.05
CY2016Q2 vktx Over Allotment Option Exercised
OverAllotmentOptionExercised
1125000
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1125000
CY2016Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1283400
CY2016Q2 vktx Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
111600
CY2016Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
19482162
CY2015Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
9783312
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
15590113
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
8120639
CY2016Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
490191
CY2015Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
835832
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
537974
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1318470
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14240487
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2012697
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q3 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
0
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
11569087
CY2016Q3 vktx Available For Sale Securities Continuous Unrealized Gain Position Accumulated Gain
AvailableForSaleSecuritiesContinuousUnrealizedGainPositionAccumulatedGain
1002
CY2016Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
7139
CY2016Q3 vktx Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
1
CY2016Q3 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
27
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
13342869
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
7370
CY2015Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
14
CY2016Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
1351135
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
13884371
CY2015Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
2370903
CY2016Q3 vktx Convertible Notes Payoff Value Current
ConvertibleNotesPayoffValueCurrent
1977813
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.025
CY2015 vktx Debt Instrument Current Maturities Due Date
DebtInstrumentCurrentMaturitiesDueDate
2016
vktx Debt Instrument Current Maturities Due Date
DebtInstrumentCurrentMaturitiesDueDate
2017
CY2015Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05
CY2016Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.025
CY2015 vktx Debt Instrument Long Term Maturities Due Date
DebtInstrumentLongTermMaturitiesDueDate
2016
vktx Debt Instrument Long Term Maturities Due Date
DebtInstrumentLongTermMaturitiesDueDate
2017
vktx Date Of Registration Rights Agreement Amendment
DateOfRegistrationRightsAgreementAmendment
2016-01-22
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
1000000
CY2014Q1 us-gaap Deferred Compensation Arrangement With Individual Exercise Price
DeferredCompensationArrangementWithIndividualExercisePrice
0.01
CY2014Q1 vktx Number Of Tranches
NumberOfTranches
2
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
168000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
633810
CY2015Q2 vktx Shares Repurchase Price Per Share
SharesRepurchasePricePerShare
0.00001
CY2015Q2 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
366190
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
61566
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
320953
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
601593
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
365394
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
520818
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50250
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
835962
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
291824
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y5M16D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.50
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.17
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.34
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.80
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0151
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
vktx Description Of Warrant
DescriptionOfWarrant
The warrant is exercisable for cash or on a cashless basis at a per share exercise price equal to $10.00 commencing on April 28, 2016, one year following the date of the prospectus filed with the SEC relating to the IPO, and expiring on April 28, 2020. The warrant also provides for registration rights upon request, under certain circumstances. The piggyback registration right provided in connection with the warrant will terminate on April 28, 2022.
vktx Warrant Expiration Date
WarrantExpirationDate
2022-04-28
vktx Initial Public Offering Expiration Date
InitialPublicOfferingExpirationDate
2020-04-28
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
63648
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
54010
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
189668
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
73640
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
247611
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
190337
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
437948

Files In Submission

Name View Source Status
0001564590-16-028979-index-headers.html Edgar Link pending
0001564590-16-028979-index.html Edgar Link pending
0001564590-16-028979.txt Edgar Link pending
0001564590-16-028979-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vktx-10q_20160930.htm Edgar Link pending
vktx-20160930.xml Edgar Link completed
vktx-20160930.xsd Edgar Link pending
vktx-20160930_cal.xml Edgar Link unprocessable
vktx-20160930_def.xml Edgar Link unprocessable
vktx-20160930_lab.xml Edgar Link unprocessable
vktx-20160930_pre.xml Edgar Link unprocessable
vktx-ex311_7.htm Edgar Link pending
vktx-ex312_6.htm Edgar Link pending
vktx-ex321_8.htm Edgar Link pending